Table 1 Summary of the study profile
Study design | Cluster randomized controlled community trial |
|---|---|
Intervention | Community health workers testing for Schistosoma mansoni infection using Point-of-care Circulating Cathodic Antigen test before offering treatment |
Control | Mass drug administration using praziquantel without testing for Schistosoma mansoni infection as per current practice |
Primary outcome | Proportion of study participants provided with praziquantel drug (treatment coverage) and geographical cluster (a service area of the community health workers) in the intervention and control arms |
Cluster eligibility criteria | Having more than 60 adult individuals served by two community health workers |
Inclusion | Individuals aged ≥18 years residing in a study cluster (s), willing to participate and give written informed consent |
Exclusion | Pregnant women at the time of treatment, history of adverse reaction to praziquantel and acutely ill at the time of treatment |
Sampling eligibility criteria | Residents of the selected clusters or residents of Kome island |
Sampling exclusion criteria | Non-resident of the cluster or Kome island as identified by community health workers participating in the study |
Sample size per arm | Total sample size (N = 4500), Intervention arm (n = 2250) and control (n = 2250) |